OncLive SOSS
  • MJHLS Brand Logo

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

© 2021 MJH Life Sciences™ and OncLive. All rights reserved.

Treating Advanced RAI-Refractory DTC: A Two-Way Street: Medical Oncology and Endocrinology

December 14, 2020
Lori J. Wirth, MD, Massachusetts General Hospital

,
Jennifer Sipos, MD, Ohio State University

,
Frank Worden, MD

Related Content:

Insights | Head & Neck Cancers
Search Continues for Agents to Provide Additive Benefit to Chemoradiation in Head and Neck Cancer
28-Gene Score May Predict Distant Metastatic Recurrence in Advanced Head and Neck Cancers
NICE Rejects Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
x